News

Clinical Care Options (CCO), the leading provider of clinical educational content and technological learning and information platforms, along with the Postgraduate Institute for Medicine, will present key findings on the ability of an online point-of-care decision support tool to affect the care of patients with multiple myeloma (MM) in a poster presentation at the 56th Annual Meeting of the American Society of Hematology (ASH) in San Francisco. The presentation, “Clinical Impact of an Internet-Based Tool to Provide Expert Guidance for Multiple Myeloma (MM) From 2012 to 2014,” will be given Saturday December 6 from 5:30 PM - 7:30 PM in Hall E of Moscone Center North.

The study, supported by unrestricted educational grants from Celgene Corporation and Millennium: The Takeda Oncology Company, provides compelling evidence of specific practice gaps among physicians caring for patients with MM that directed the design of an interactive decision support tool to help guide therapeutic approaches. In addition to the presentation at ASH, the abstract was also published in the November 14 supplemental issue of Blood. The presentation was authored by: Kenneth Anderson, MD, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute; Andrew D. Bowser, ELS, CCMEP, CCO; Erik Brady, PhD, CCMEP, CCO; Davecia R. Cameron, MS, CCO; Sagar Lonial, MD, The Winship Cancer Institute, Emory University; Amitabha Mazumder, MD, New York University Cancer Center; Jim Mortimer, CCO; Kevin L. Obholz, PhD, CCO.

Clinical practice guidelines in MM list multiple therapeutic choices, with similar levels of evidence, but frequently lack recommendations tailored for individual patient cases. The authors of the study sought to determine whether expert recommendations on MM treatment, based on specific disease and patient characteristics and delivered via an interactive online decision support tool, would affect the planned treatment decisions of community practitioners. The study showed that the majority of practitioners (71%) using the online decision support tool either confirmed or changed their planned treatment approaches for specific MM patient cases, suggesting that interactive tools offering expert recommendations can clarify selection of therapy in induction, maintenance, and relapsed/refractory settings for patients with MM.

“CCO is dedicated to helping clinicians make optimal treatment decisions through the combination of expert educational content and innovative technology,” said Trish Bates Doolin, Executive Vice President and General Manager, CCO Oncology. “We are honored to have this important educational data from our program selected by the ASH committee and to be shared at the same venue with world-class clinical studies at the annual meeting.”

About Clinical Care Options 
Clinical Care Options, LLC, is the leader in the development of innovative educational technology platforms that integrate all levels of medical education and information with personalization and moderated social media. CCO has been a pioneer in the creation of continuing education and decision support resources for healthcare professionals both in the United States and around the globe for more than a decade. For more information, visit clinicaloptions.com.